Effect of Maternal Age and BMI on Induction of Labor Using Oral Misoprostol in Late-term Pregnancies: a Retrospective Cross-sectional Study
1 other identifier
observational
104
1 country
1
Brief Summary
To evaluate the effect of maternal age and body mass index (BMI) on oral misoprostol induction of labor for late-term pregnancies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2023
CompletedStudy Start
First participant enrolled
December 1, 2023
CompletedFirst Posted
Study publicly available on registry
December 28, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2024
CompletedDecember 28, 2023
December 1, 2023
1 month
November 18, 2023
December 14, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety and tolerability of misoprostol for induction of labor
Efficacy induction of labor for late term pregnancies according to age and BMI
290 days of pregnancy
Interventions
Oral misoprostol for induction of labor in late term pregnancies
Eligibility Criteria
term (37 weeks or more of gestation) singleton pregnancies in women who have not had a previous cesarean delivery and a bishop score \< 7.
You may qualify if:
- Late term pregnancies out of labor,
- Bishop score \< 7
You may not qualify if:
- labor (defined as presence of at least three painful uterine contractions every ten minutes),
- uterine tachysystole (\>5 contractions within 10 minutes for two consecutive 10-minute periods),
- hypertonic uterus,
- abnormal CTG,
- contraindications to vaginal delivery (fetal malpresentation such as breech presentation or transverse situation, fetal macrosomia, abnormally implanted placenta, active genital herpes infection, cervical cancer),
- patients with parity \> 4,
- medical contraindication to misoprostol (asthma, glaucoma),
- women with previous hysterotomies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Andrea Etrusco
Palermo, 90123, Italy
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
November 18, 2023
First Posted
December 28, 2023
Study Start
December 1, 2023
Primary Completion
January 1, 2024
Study Completion
January 1, 2024
Last Updated
December 28, 2023
Record last verified: 2023-12